Jazz Pharmaceuticals (JAZZ) Tops Q2 EPS by 48c

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $3.90, $0.48 better than the analyst estimate of $3.42. Revenue for the quarter came in at $751.8 million versus the consensus estimate of $735.62 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2021 EPS of $13.40-$14.70, versus the consensus of $14.45. Jazz Pharmaceuticals sees FY2021 revenue of $3.02-3.18 billion, versus the consensus of $3.11 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• ATRenew Inc (RERE) Tops Q2 EPS by 8c ; Offers Guidance
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics